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Background: Special AT-rich sequence binding protein 1 (SATB1) is a nuclear factor that functions as the global
chromatin organizer to regulate chromatin structure and gene expression gene expression. SATB1 has been shown
to be abnormally expressed in various types of cancer. However, the expression and role of SATB1 in prostate
cancer remain unclear.
Methods: 120 cases of prostatic carcinoma and 60 cases of benign prostate hyperplasia were analyzed for SATB1
expression by immunohistochemistry. LNCaP, DU-145, and PC3 prostate cancer cells were examined for SATB1
expression by Western blot analysis. Cell proliferation and invasion was evaluated by CCK8 and transwell invasion
assay, respectively.
Results: SATB1 staining was stronger in prostatic carcinomas with metastasis than in those without metastasis, but
was absent in benign prostate hyperplasia. Furthermore, SATB1 expression was positively correlated with bone
metastasis and the Gleason score. SATB1 overexpression promoted the proliferation and invasion of LNCaP cells
while SATB1 knockdown inhibited the proliferation and invasion of DU-145 cells.
Conclusions: These findings provide novel insight into oncogenic role of SATB1 in prostate cancer, suggesting that
SATB1 is a promising biomarker and therapeutic target for prostate cancer.
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Prostate cancer is the most frequent cancer among men
over 50 years old in industrialized countries. With the
development of PSA screening, MRI imaging and new
prostate biopsies protocols, the accuracy of detection
and localization of prostate tumors has been increased,
but still 5% of cases present with metastatic lesions at
the time of diagnosis [1]. The most common site of me-
tastasis for prostate cancer is bone, and frequently me-
tastasis is symptomatic, with pain, debility, and
functional impairment [2]. Therefore, it is important to
investigate the molecular mechanisms underlying the
progression and metastasis of prostate cancer to provide* Correspondence: maolijunxz@163.com
†Equal contributors
2Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical
College, Xuzhou 221002, China
Full list of author information is available at the end of the article
© 2013 Mao et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orbetter strategies for the prevention and therapy of pros-
tate cancer.
Overexpression of embryonic transcription factors has
been linked to cancer development and progression. In-
appropriate expression of these transcription factors is
thought to reinstitute developmental programs out of
context, and contributing to tumor formation and pro-
gression. Special AT-rich sequence binding protein 1
(SATB1) is a nuclear factor that functions as the global
chromatin organizer to regulate chromatin structure and
gene expression [3]. SATB1 has been shown to be ab-
normally expressed in various types of cancer and is pro-
posed as an oncogene which promotes malignancy [4-6].
However, the expression and role of SATB1 in prostate
cancer remain unclear.
In this study, we performed immunohistochemistry
analysis to examine the expression of SATB1 in clinical
prostatic carcinoma samples and analyze the correlationd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Mao et al. Journal of Translational Medicine 2013, 11:111 Page 2 of 10
http://www.translational-medicine.com/content/11/1/111of SATB1 expression with the clinicopathological fea-
tures of prostate cancer. Furthermore, we used a panel
of prostate cancer cell lines including LNCaP, DU145,
and PC3 to investigate the function of SATB1 in prostate
cancer cell proliferation and invasion.
Methods
Tissue microarray and immunohistochemistry
Total 120 cases of prostate carcinoma were enrolled
in the present study. The patients had undergone
surgical resection at the affiliated hospital of Xuzhou
Medical College between 2006 and 2012. Among the
120 cases of prostate carcinoma, 60 cases had metas-
tasis to the bone including one case with additional
metastasis to the lung and two cases with additional
metastasis to lymph node. For the other 60 cases
without metastases, they were newly diagnosed and
had no recurrence or bone disease. 60 cases of be-
nign prostate hyperplasia were also included in this
study, including 20 from open prostatectomies and
40 from transurethral plasmakinetic enucleation of
prostate. The immunohistochemical analysis was
performed by pathologists at the affiliated hospital of
Xuzhou Medical College to detect SATB-1 expression
in 60 cases of prostatic carcinoma with metastases,
60 cases of prostatic carcinoma without metastases,
and 60 cases of benign prostate hyperplasia. Briefly,
the samples were fixed in 40 g/L paraformaldehyde,
wax-embedded and cut into 4 μm serial sections.
Next, endogenous peroxidases were quenched and
the sections were washed carefully with 0.01 M phos-
phate buffered saline (PBS) for three times. The sec-
tions were blocked with 2% goat serum in 0.01 M
PBS at room temperature for 1 h, then incubated
with rabbit polyclonal anti-SATB1 antibody (1:500 di-
lution, NB110-17780, Novus Biologicals, Littleton,
CO, USA) overnight at 4°C. Afterwards, the sections
were incubated with goat anti-rabbit horseradish
peroxidase-conjugated secondary antibody and avidin-
biotin complex followed by diaminobenzidine (Vector
ABC, Burlingame, CA, USA). For negative control,
tissue was incubated with rabbit IgG serum.
The immunohistochemical staining was scored by pa-
thologists based on the intensity and percentage of cells
with SATB1 nuclear staining as follows: score 0, negative
nuclear staining of almost all tumor cells; score 1, weak
nuclear staining of almost all tumor cells; score 2, mod-
erate nuclear staining of more than 50% tumor cells or
strong nuclear staining of more than 5% tumor cells.
Samples that could not be interpreted or missed most of
the tumor tissue were given a score of not applicable
(N/A). Scoring of the tissue microarray was performed
by three independent observers. Significance of correl-
ation between SATB1 staining and histopathologicalfactors was determined using Pearson’s chi-squared (x2)
test.
Cell culture and transfection
The human prostate cancer cell line LNCaP, DU-145,
and PC-3 were obtained from Institute of Biochemistry
and Cell Biology, Chinese Academy of Sciences (Shang-
hai, China) and cultured in RPMI-1640 medium (Gibco,
USA) supplemented with 10% fetal calf serum (Hyclone,
USA), penicillin and streptomycin at 37°C in 5% CO2.
Cells were regularly passaged to maintain exponential
growth. SATB1 expression vector pcDNA3.1-SATB1 or
SATB1 specific shRNA pSilencer3.1-SATB1 (the se-
quences of the oligos that targeted SATB1 were as follows:
5′-CACCGGATTTGGAAGAGAGTGTCTTCAAGAGAG
ACACTCTCTTCCAAATCCTTTTTTG-3′, 63 bp) was
constructed and transfected into cells using lipofectamin
2000 (Invitrogen, USA) according to the manufacturer’s in-
structions. Cells transfected with pcDNA3.1 or pSliencer3.1
empty vector were used as negative control. The cells were
harvested at different time points after transfection for the
following experiments.
Western blotting
Cells were collected and lysed with RIPA lysis buffer
(Santa Cruz Biotechnology, USA). The cell lysates were
collected after centrifugation and the protein concentra-
tion was quantified by bovine serum albumin (BSA)
method. Equal amount of protein was loaded and sepa-
rated on 10% SDS-PAGE, and then transferred to nitro-
cellulose membranes (Millipore, USA). The membranes
were blocked in 3% BSA for 2 h and then incubated with
SATB1, SATB2 or β-actin antibody (Santa Cruz Biotech-
nology, USA) at 4°C overnight. After three times of
washing with TBST,the membranes were incubated
with HRP-conjugated secondary antibodies (Santa Cruz
Biotechnology, USA) for 1 h at room temperature. The
membranes were developed using ECL kit (Santa Cruz
Biotechnology, USA) and exposed to X-ray film. β-
actin was used as loading control. The density of the
bands on the membrane were scanned and analyzed
with an image analyzer (LabWorks Software, UVP Up-
land, CA, USA).
Cell proliferation assay
The proliferation of DU145 cells was examined using
CCK-8 kit (Tongren Shanghai Co. China) according to
the manufacturer’s instructions. Briefly, the cells were
seeded into 96-well plates with 5 × 103 cells/well and
cultured for 48 h. Then 10 μl CCK-8 solution was added
to each well and incubated for 1 h. The absorbance (A)
at 450 nm was measured using a microplate reader. Re-
sults were representative of three individual experiments
in triplicate.
Figure 1 SATB1 immunohistochemistry staining. A, benign prostate hyperplasia. B, prostatic carcinoma with metastasis. C, prostatic carcinoma
without metastasis. D, negative control. Magnification: 400 × .
Table 1 SATB1 expression and clinicopathologic
parameters of prostate cancer
parameter cases SATB1 expression P value
- + ++ +++
metastases
+ 30 2 4 14 10
- 30 6 9 12 3 0.006 <0.05
Age (year)
≤70 37 5 8 16 8
>70 23 3 5 10 5 0.837 >0.05
PSA(ng/ml)
≤20 21 4 3 8 6
>20 39 4 10 18 7 0.713 >0.05
Gleason score
2-4 17 4 7 5 1
5-7 20 3 2 11 4
8-10 23 1 4 10 8 0.009 <0.05
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The invasion ability of DU145 cells was detected using 24-
well transwell cell culture chambers (6.5 mm diameter,
8.0 μm pore size, polycarbonate membrane, Corning,
USA). Briefly, an aliquot of 105 cells were added into the
upper chamber with 100 uL serum-free medium. The lower
chamber was filled with 0.6 ml medium containing 10%
FBS. After 20 h incubation at 37°C in 5% CO2 incubator,
the cells on the upper surface of the filters were removed
by wiping with a cotton swab. The filters were fixed in 4%
paraformaldehyde and stained with Crystal Violet. The
stained cells were counted under a microscope in five ran-
domly selected fields. At least three chambers from three
different experiments were analyzed.
Statistical analysis
The results were expressed as mean ± SD. Statistical
analysis was performed using Student’s t test or a 1-way
or 2-way analysis of variance (ANOVA) test followed by
Tukey’s test. P < 0.05 was considered to be statistically
significant.
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SATB1 expression is correlated with clinicopathological
features of prostate cancer
SATB1 expression in prostate cancer tissues was exam-
ined by immunohistochemistry. The results showed
that the positive rate of SATB-1 staining was 86.7%
(104/120) in 120 cases of prostatic carcinoma and 0%
(0/60) in 60 cases of benign prostate hyperplasia.








Figure 2 SATB1 expression is correlated with the invasion ability of p
cells was measured by Transwell chamber. A, DU-145. B, PC-3.C, LNCaP. Ma
of SATB1 in LNCaP, DU-145 and PC-3 cells (n = 3). β-actin served as loading
antibody could not detect SATB2 protein in the cell lysateshyperplasia (Figure 1A), but was positively stained in
the nucleus of prostate cancer cells (Figure 1B,C). In
addition, SATB1 staining was stronger in cells of prostatic
carcinoma with metastasis than in those of prostatic
carcinoma without metastasis.
Furthermore, we analyzed the correlation of SATB1
expression with clinicopathological features of prostate
cancer. The results shown in Table 1 demonstrated that
SATB1 expression was positively correlated with the1 Ab
SATB2 Ab
rostate cancer cells. A-C: The invasion of LNCaP, DU-145 and PC-3
gnification: 200×. D: Western blot analysis of the relative protein level
control. *P < 0.05 compared to DU-145 cells. Note that SATB1
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not with patient age or the concentration of prostate-
specific antigen in blood serum (P > 0.05). These data
suggest that SATB-1 expression is closely related with
the occurrence and development of prostate cancer.
SATB1 expression level is correlated with the invasion
ability of prostate cancer cells
Since SATB1 expression is positively correlated with the
bone metastasis of prostate cancer, we hypothesized that
SATB1 expression may confer high invasion ability in
prostate cancer cells. Therefore, we selected several
prostate cancer cell lines LNCaP, DU-145 and PC-3 with
different invasion ability. Transwell invasion assay dem-































Figure 3 Silencing of SATB1 in DU-145 cells. DU-145 cells were untrans
transfected with pSilencer3.1-SATB1 vector for 24 h, 48 h, or 72 h. The prot
(n = 3). β-actin served as loading control. *P < 0.05 compared to cells transfmembrane was 98.6 ± 8.5 in DU-145 cells, 68.5 ± 7.1 in
PC-3 cells, and 42.7 ± 4.5 in LNCaP cells (Figure 2A-C).
Western blot analysis showed that the ratio of SATB1/β-
actin was 0.72 ± 0.03, 0.42 ± 0.02, 0.39 ± 0.02 in DU-145,
PC-3, and LNCaP cells, respectively (Figure 2D). These
results demonstrate that the invasion ability of these
three cancer cell lines was consistent with the protein
expression level of SATB1, indicating the potential role
of SATB1 in prostate cancer metastasis.
Silencing of SATB1 inhibits the invasion and growth of
DU-145 cells
To investigate the role of SATB1 in the invasion of
prostate cancer cells, we employed the loss of func-










fected (control), transfected with pSliencer3.1 control vector or
ein levels of SATB1 and SATB2 were detected by Western blot analysis
ected with pSliencer3.1.
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high. Western blot analysis showed that after the
transfection of pSilencer3.1-SATB1 into DU145 cells,
protein level of SATB1 decreased in a time dependent
manner and reached 31.4 ± 9.0% of the control at
72 h after transfection, while protein level of SATB2
remained unchanged (Figure 3). These results demon-




























Figure 4 Silencing of SATB1 inhibits the invasion and growth of DU-1
Transwell chamber. A, DU-145 cells untransfected. B, DU-145 cells transfect
SATB1. Magnification: 200×. D: Quantitative analysis of the number of invad
was determined by CCK8 assay (n = 3). The cell proliferation inhibition rate
transfection with pSilencer3.1-SATB1. *P < 0.05 compared to cells transfecteSATB1 expression in DU145 cells effectively and
specifically.
Next we performed transwell invasion assay and the
results demonstrated that the number of cells that in-
vaded the membrane was 96.5 ± 6.5 in untransfected
DU-145 cells, 90.0 ± 5.4 in DU-145 cells transfected with
control vector, and 34.2 ± 4.2 in DU-145 cells transfected












45 cells. A-D: The invasion of DU-145 cells was measured by
ed with pSliencer3.1. C, DU-145 cells transfected with pSilencer3.1-
ed cells as shown in A-C (n = 3). E: The proliferation of DU-145 cells
was calculated for DU-145 cells at 24 h, 48 h and 72 h after
d with pSliencer3.1.
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using CCK-8 kit and the results showed that the pro-
liferation of DU-145 cells was inhibited at 53.2 ± 5.8%,
62.3 ± 4.0%, and 76.7 ± 3.0% at 24 h, 48 h, 72 h after
transfecion of SATB1 shRNA, respectively (Figure 4E).
Collectively, these results suggest that silencing of
SATB1 inhibits the invasion and growth of prostate
cancer cells.Overexpression of SATB1 promotes the invasion and
growth of LNCaP cells
To further confirm the role of SATB1 in the invasion of
prostate cancer cells, we employed the gain of function
approach to overexpress SATB1 in LNCaP cells in which
SATB1 expression is relatively low. RT-PCR analysis
showed that after the transfection of pcDNA3.1-SATB1
into LNCaP cells, mRNA level of SATB1 increased in a
time dependent manner and reached 304.54 ± 9.89% of
the control at 36 h after transfection (Figure 5A). Simi-
larly, Western blot analysis showed that after the trans-
fection of pcDNA3.1-SATB1 into LNCaP cells, protein
level of SATB1 increased in a time dependent manner
and reached 334.74 ± 4.07% of the control at 36 h after
transfection (Figure 5B). These results demonstrate that
the SATB1 expression construct we designed could ef-
fectively increase SATB1 expression to a high level in
LNCaP cells.
Transwell invasion assay demonstrated that the num-
ber of cells that invaded the membrane was 131.0 ± 7.9
in untransfected LNCaP cells, 130.3 ± 5.5 in LNCaP cells
transfected with control pcDNA3.1 vector, and 288.3 ±





Figure 5 Reconstitution of SATB1 expression in LNCaP cells. LNCaP ce
vector or transfected with pcDNA3.1-SATB1 vector for 12 h, 24 h, or 36 h. A
protein level of SATB1 was detected by Western blot analysis (n = 3). β-act
with pcDNA3.1.Furthermore, CCK-8 cell proliferation assay showed
that the proliferation ratio was 25.3 ± 2.6%, 37.1 ± 3.7%,
and 64.6 ± 2.9% in LNCaP cells at 24 h, 48 h and 72 h
after transfection with pcDNA3.1-SATB1 vector, respect-
ively, but was only 10.7 ± 1.2%, 12.1 ± 1.2%, and 13.3 ±
1.1% in LNCaP cells transfected with pcDNA3.1 control
vector, respectively (Figure 6E). Taken together, these re-
sults suggest that SATB1 promotes the invasion and
growth of prostate cancer cells.
Discussion
As the second cause for cancer-related death, prostate
cancer is a global public health problem. Unfortunately,
up to now very limited information is available to dis-
cern which cases of prostate cancer are likely to remain
latent, versus those that are likely to metastasize and
warrant more aggressive management [7]. Therefore,
there is urgent need to identify novel biomarkers of
prostate cancer that could distinguish benign versus ma-
lignant or even metastatic prostate cancer.
SATB1 is an important transcription factor that
plays a critical role in the early embryonic develop-
ment and the formation of tissues and organs [8].
Recent studies suggest that SATB1 modulates cell
proliferation and lineage development and is impli-
cated in breast cancer [9]. However, the functional
role of SATB1 in prostate cancer progression and me-
tastasis remains elusive.
In this study we first examined the expression of
SATB1 in clinical prostate cancer tissues. The immuno-
histochemistry analysis showed that SATB1 staining was
stronger in prostatic carcinoma with metastasis than in
prostatic carcinoma without metastasis, but was absent
in benign benign prostate hyperplasia. Furthermore, our* *
pcDNA3.1-SATB1
lls were untransfected (control), transfected with pcDNA3.1 control
. The mRNA level of SATB1 was detected by RT-PCR (n = 3). B. The



















Figure 6 Overexpression of SATB1 promotes the invasion and growth of LNCaP cells. A-D: The invasion of LNCaP cells was measured by
Transwell chamber. A, LNCaP cells untransfected. B, LNCaP cells transfected with pcDNA3.1. C, LNCaP cells transfected with pcDNA3.1-SATB1.
Magnification: 200×. D: Quantitative analysis of the number of invaded cells as shown in A-C (n = 3). *P < 0.05 compared to cells transfected with
pcDNA3.1. E: The proliferation of LNCaP cells was determined by CCK8 assay (n = 3). The cell proliferation ratio was calculated for LNCaP cells at
24 h, 48 h and 72 h after transfection of pcDNA3.1 or pcDNA3.1-SATB1. *P < 0.05 compared to corresponding cells transfected with pcDNA3.1.
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correlated with the bone metastasis and the Gleason
score. These data suggest that SATB1 expression is cru-
cially implicated in the progression and metastasis of
prostate cancer.
To provide further evidence that SATB1 contributes to
prostate cancer development, we employed several pros-
tate cancer cell lines LNCaP, DU-145 and PC-3, and
performed gain and loss of function experiments. We
found that SATB1 protein level was the highest in DU-
145 cells, which corresponds well with its high invasion
ability. Meanwhile SATB1 protein level was the lowest
in LNCaP cells, which corresponds well with its low in-
vasion ability. Based on these results, we speculated thatSATB1 expression is correlated with the invasion ability
of prostate cancer cells. Next we knockdown SATB1 ex-
pression in DU-145 cells and found that the depletion of
SATB1 led to decreased cell invasion and proliferation.
Moreover, when we overexpressed SATB1 in LNCaP
cells, we found that this resulted in increased cell inva-
sion and proliferation. Therefore, both gain and loss of
function approaches demonstrate that SATB1 promotes
prostate cancer cell invasion and proliferation in vitro,
and these results are consistent with the data on the
clinical prostate cancer samples.
However, further studies are important to investigate
the molecular mechanisms by which SATB1 promotes
the malignant behaviors of prostate cancer cells. SATB1
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‘cage-like’ protein distribution surrounding the hetero-
chromatin. This architecture is proposed as “SATB1
regulatory network” by which SATB1 regulates gene ex-
pression via the recruitment of chromatin remodelling/
modifying enzymes and transcription factors to genomic
DNA [10-12]. Upon the activation of T-helper 2 cells,
SATB1 becomes expressed and folds the cytokine-gene
locus into dense loops for rapid induction of multiple
cytokine genes [13]. In breast cancer cells, SATB1 coor-
dinates the expression of a large number of genes to in-
duce metastasis. Removal of SATB1 from aggressive
breast cancer cells not only reversed metastatic pheno-
types but also inhibited tumor growth, indicating its key
role in breast cancer progression [9].,Barboro et al.
reported that the interaction of SATB1 with specialized
DNA sequences called matrix attachment regions
(MARs) was important for the aggressive potential of
prostate cancer cells [14]. In addition, a very recent
study showed that knockdown of SATB1 in highly ag-
gressive prostate cancer PC-3 M cells inhibited tumor
growth and invasion along with increased E-cadherin ex-
pression, suggesting that SATB1 promotes prostate can-
cer aggressiveness through epithelial-mesenchymal
transition [15]. Thus we speculate that SATB1 modu-
lates gene expression to regulate the proliferation and
invasion of prostate cancer cells. In this context, it is im-
portant to identify the downstream target genes of
SATB1 that are involved in cell proliferation and inva-
sion. For example, Bcl-2 and c-myc have been reported
recently as the targets of SATB1 [16,17]. In our future
investigations, we will examine the expression of these
important SATB1 targets in prostate cancer cells, to pro-
vide novel insights into the potential oncogenic role of
SATB1 in prostate cancer.
On the other hand, a recent study reported that miR-448
could target SATB1 and suppress its expression in breast
cancer cells, and miR-448 was downregulated during epi-
thelial–mesenchymal transition, an important process of
tumor metastasis [18]. Therefore, we speculate that dur-
ing prostate cancer metastasis the downregulation of
miR-448 may contribute to the upregulation of SATB1,
which may explain our observation that SATB1 expres-
sion was positively correlated with the bone metastasis
of prostate cancer. Further studies are needed to test this
possibility.
Conclusions
SATB1 expression is positively correlated with the bone
metastasis and the Gleason score of prostatic carcinoma.
SATB1 overexpression promotes prostate cancer cell
proliferation and invasion while SATB1 knockdown in-
hibits prostate cancer cell proliferation and invasion.
These findings provide novel insight into the oncogenicrole of SATB1 in prostate cancer, suggesting that SATB1
is a promising biomarker and therapeutic target for
prostate cancer.
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